On Monday, Ascendis Pharma A/S ADR (NASDAQ: ASND) opened higher 4.05% from the last session, before settling in for the closing price of $170.80. Price fluctuations for ASND have ranged from $111.09 to $183.00 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 92.27% over the past five years. Company’s average yearly earnings per share was noted 36.71% at the time writing. With a float of $59.94 million, this company’s outstanding shares have now reached $60.37 million.
In terms of profitability, gross margin is 85.3%, operating margin of -90.54%, and the pretax margin is -91.75%.
Ascendis Pharma A/S ADR (ASND) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Ascendis Pharma A/S ADR is 0.72%, while institutional ownership is 108.13%. The most recent insider transaction that took place on May 12 ’25, was worth 312,384. Before that another transaction happened on May 07 ’25, when Company’s Officer proposed sale 10,938 for $162.20, making the entire transaction worth $1,774,164.
Ascendis Pharma A/S ADR (ASND) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 36.71% per share during the next fiscal year.
Ascendis Pharma A/S ADR (NASDAQ: ASND) Trading Performance Indicators
Check out the current performance indicators for Ascendis Pharma A/S ADR (ASND). In the past quarter, the stock posted a quick ratio of 0.71. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 27.23.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -6.29, a number that is poised to hit -1.56 in the next quarter and is forecasted to reach 2.10 in one year’s time.
Technical Analysis of Ascendis Pharma A/S ADR (ASND)
Ascendis Pharma A/S ADR (NASDAQ: ASND) saw its 5-day average volume 0.36 million, a negative change from its year-to-date volume of 0.5 million. As of the previous 9 days, the stock’s Stochastic %D was 54.68%. Additionally, its Average True Range was 6.74.
During the past 100 days, Ascendis Pharma A/S ADR’s (ASND) raw stochastic average was set at 91.86%, which indicates a significant decrease from 92.60% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 38.58% in the past 14 days, which was lower than the 48.77% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $161.58, while its 200-day Moving Average is $143.11. Nevertheless, the first resistance level for the watch stands at $180.63 in the near term. At $183.54, the stock is likely to face the second major resistance level. The third major resistance level sits at $188.91. If the price goes on to break the first support level at $172.35, it is likely to go to the next support level at $166.98. The third support level lies at $164.07 if the price breaches the second support level.
Ascendis Pharma A/S ADR (NASDAQ: ASND) Key Stats
There are currently 61,091K shares outstanding in the company with a market cap of 10.73 billion. Presently, the company’s annual sales total 393,500 K according to its annual income of -409,120 K. Last quarter, the company’s sales amounted to 106,360 K and its income totaled -99,690 K.
